EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GLAXF

GLAXF

GSK plc

Next earnings Jul 28, 2026 · consensus $0.46 EPS, $8.48B rev

Sell
$25.33
▲ 0.00%
$25.33▲ +36.13%
over 1Y
L $16.36EODHDH $30.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-1.4%
1M-0.9%
3M-6.2%
YTD+9.1%
1Y+36.1%
OverviewValuationQualityFilings
Rating
Sell
Quality
—
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 32 analysts
Buy

Mixed signals in the latest filings.

GSK plc shows limited reported revenue.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$109B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-06-262026-06-26open ↗SC TO-T/AFiling2026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗SC TO-TFiling2026-06-24open ↗6-KPeriod ending 2026-06-232026-06-23open ↗6-KPeriod ending 2026-06-222026-06-22open ↗11-KPeriod ending 2025-12-312026-06-17open ↗11-KPeriod ending 2025-12-312026-06-17open ↗6-KPeriod ending 2026-06-172026-06-17open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-06-122026-06-12open ↗

Quality score

—
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
Momentum—
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is GSK plc (GLAXF) a buy?
GLAXF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Sources: SEC EDGAR (CIK 0001131399, latest 6-K filed 2026-06-26) · EODHD · as of 6/20/2026, 7:30:55 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-12-11
GSK plc
10% owner
Buy1.47M @ $19.00$27.9M
2024-09-27
GSK plc
10% owner
Buy2.79M @ $8.00$22.3M
2023-12-07
GSK plc
10% owner
Buy3.30M @ $5.00$16.5M
2022-09-16
GSK PLC
Insider
Disposed (J)9.64M @ $9.75$94.0M

Dividends

Quarterly
Yield (TTM)
4.3%
Annual / share
$1.09
Last ex-date
2026-05-15
Last amount
$0.23
ex 2026-05-15paid 2026-07-09$0.23
ex 2026-02-20paid 2026-04-09$0.23
ex 2025-11-14paid 2026-01-08$0.21
ex 2025-08-15paid 2025-10-09$0.21
ex 2025-08-14$0.22
ex 2025-05-16paid 2025-07-10$0.21

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Recent news

market news →
GSK (LSE:GSK) Wins FDA Approval For Utebzi As Momelotinib Gains Orphan TagBullish
finance.yahoo.com· 2026-06-26
FDA Expands IONS' Tryngolza Label to Treat Severe HypertriglyceridemiaBullish
finance.yahoo.com· 2026-06-25
Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?Bullish
finance.yahoo.com· 2026-06-24
Top Analyst Reports for Micron Technology, Coca-Cola & Arista NetworksBullish
finance.yahoo.com· 2026-06-23
3 Top Dividend Stocks to Maximize Your Retirement IncomeBullish
finance.yahoo.com· 2026-06-23
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsBullish
finance.yahoo.com· 2026-06-21

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score— vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 24d
Bullish
+0.17
vs typical · 39 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.